KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.

Cyrille Touzeau, Brea Lipe, Abdullah M Khan, Binod Dhakal, Sandhya Nair, Jianming He, João Mendes, Seina Lee, Carolina Lonardi, Ana Slaughter, Nikoletta Lendvai, Jordan M Schecter, Diana Chen, Man Zhao, Tzu-Min Yeh, Xavier Leleu, Noemí Puig, Dominik Dytfeld, Elena Zamagni, Katja Weisel, Lionel Karlin, Michel Delforge, Paolo Corradini, Roberto Mina, Wilfried Roeloffzen, Surbhi Sidana

Adv Ther 42(10) 5023-5041

PMID40768190
PMCIDPMC12474644
DOI10.1007/s12325-025-03308-2
发表日期2025-08-06
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

INTRODUCTION: Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (NCT04181827), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1-3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician's choice of treatment for lenalidomide-refractory MM. METHODS: De-identified data from the Flatiron Health MM cohort registry (January 2020 to May 2024) were compared with data from CARTITUDE-4 (data cutoff May 1, 2024). Key eligibility criteria for CARTITUDE-4 were used to match patients from the Flatiron database. Baseline covariates of prognostic significance were adjusted using inverse probability of treatment weighting. Outcomes for comparative effectiveness included progression-free survival (PFS), RW PFS, time to next treatment (TTNT), and overall survival (OS). Sensitivity analyses were conducted. RESULTS: The CARTITUDE-4 cohort included data from 208 patients who received cilta-cel; the median follow-up was 33.6 months. The real-world cohort included 932 patients (1445 eligible LOT) from the Flatiron database; the median follow-up was 23.6 months. In base case analyses, compared with the Flatiron cohort, patients treated with cilta-cel had improved PFS (hazard ratio [HR] 0.29 [95% confidence interval (CI)] 0.22-0.36; p < 0.001), RW-PFS (HR 0.29 [95% CI 0.23-0.37]; p < 0.001), TTNT (HR 0.32 [95% CI 0.25-0.41]; p < 0.001), and OS (HR 0.59 [95% CI 0.41-0.84]; p = 0.003). These findings were consistent across all sensitivity analyses. CONCLUSION: Cilta-cel lengthened TTNT and demonstrated meaningful prolongation in PFS and OS compared with real-world physician's choice for lenalidomide-refractory MM. These data highlight the value of cilta-cel as an effective therapy in earlier-line patients with relapsed, lenalidomide-refractory MM exposed to proteasome inhibitors and immunomodulatory drugs. TRIAL REGISTRATION: CARTITUDE-4: ClinicalTrials.gov ID NCT04181827.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。